Trends in the Global Burden of Glomerulonephritis
- PMID: 36719156
- PMCID: PMC10101604
- DOI: 10.2215/CJN.0000000000000029
Trends in the Global Burden of Glomerulonephritis
Conflict of interest statement
V. Jha reports grant funding from Baxter Healthcare, Biocon, and GSK; honoraria from AstraZeneca, Baxter Healthcare, Bayer, Boeringer Ingelheim, NephroPlus, and Zydus Cadilla—all paid to the organization; an advisory or leadership role for NephroPlus; and speakers bureau for AstraZeneca and Baxter Healthcare. The remaining author has nothing to disclose.
Comment on
-
Global, Regional, and National Burden of CKD due to Glomerulonephritis from 1990 to 2019: A Systematic Analysis from the Global Burden of Disease Study 2019.Clin J Am Soc Nephrol. 2023 Jan 1;18(1):60-71. doi: 10.2215/CJN.0000000000000017. Clin J Am Soc Nephrol. 2023. PMID: 36719159 Free PMC article.
References
-
- Foreman KJ Marquez N Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018;392(10159):2052-2090. doi: 10.1016/s0140-6736(18)31694-5 - DOI - PMC - PubMed
-
- GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1250-1284. doi: 10.1016/S0140-6736(20)30750-9 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
